+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a first-in-human clinical trial to study DPTX3186 in adults with solid tumors activated by the Wnt pathway, including cancers such as colorectal, gastric, lung, and triple-negative breast cancer. This study targets patients for whom no other approved treatments exist. The main goals are to evaluate the safety, how the body processes the drug, and initial signs of the drugs activity, while also exploring biological markers that might indicate how well the treatment works. Participants will receive DPTX3186 as a single oral dose once daily in the morning under fasting conditions for four consecutive days followed by a three-day break, completing a 28-day treatment cycle. The study uses a dose escalation approach to determine the appropriate dose and will monitor patients throughout the treatment period. During the trial, participants will be closely monitored for any treatment-related side effects and serious adverse events over up to 36 months. Eligibility includes having measurable tumors confirmed by imaging and good overall health status. The study team will collect information on treatment safety and drug behavior in the body to better understand the drugs potential and guide future research.

Age: 18Years +All GendersPhase 1
8 locations